1. AB0524 Biological agents survival comparisons among different rheumatic disease - brazilian register of biological agents in rheumatic diseases - biobadabrasil. (23rd January 2014) Authors: Fafá, B.; Valim, V.; Peçanha, P.; Laurindo, I.; Ranzolin, A.; Hayata, A.; Duarte, Â.; Brenol, C.; Carvalho, H.; Pinheiro, G. C.; Silveira, I.; Pereira, I. A.; Costa, I.; Macieira, J.; Miranda, J. R.; Moraes, J. C.; Barbosa, L. S. G.; Bértolo, M.; Sauma, M.; Silva, M. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A949 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded DNA–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus. Issue 8 (15th June 2018) Authors: Doria, A.; Stohl, W.; Schwarting, A.; Okada, M.; Scheinberg, M.; van Vollenhoven, R.; Hammer, A. E.; Groark, J.; Bass, D.; Fox, N. L.; Roth, D.; Gordon, D. Journal: Arthritis & rheumatology Issue: Volume 70:Issue 8(2018) Page Start: 1256 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FRI0222 Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Proposed Rituximab Biosimilar (GP2013) vs. EU-Approved Rituximab (RTX) in Patients with Rheumatoid Arthritis: Results from A Randomized Controlled Trial (GP13-201) over 52 Weeks. (15th July 2016) Authors: Smolen, J.; Scheinberg, M.; Tony, H.-P.; Zhu, P.; Shisha, T. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 512 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. LB0001 Efficacy and Safety of Subcutaneous Belimumab plus Standard Care in Patients with Systemic Lupus Erythematosus (SLE) with Low Complement and Positive Anti-DSDNA. (15th July 2016) Authors: Doria, A.; Stohl, W.; Schwarting, A.; Okada, M.; Scheinberg, M.; van Vollenhoven, R.; Hammer, A.E.; Groark, J.; Bass, D.; Fox, N.L.; Roth, D.; Gordon, D. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 70 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. OP0116 Effects of Blisibimod, a Subcutaneous Inhibitor of B Cell Activating Factor, in Patients with SLE. (23rd January 2014) Authors: Furie, R.; Scheinberg, M.; Leon, G.; Ramiterre, E. B.; Thomas, M.; Chu, A. D.; Hislop, C.; Martin, R. S.; Petri, M. A. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A90 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. OP0129 Effects of Blisibimod, an Inhibitor of B-Cell Activating Factor, on Markers of Renal Disease in Patients with SLE. (23rd January 2014) Authors: Furie, R.; Scheinberg, M.; Leon, G.; Ramiterre, E. B.; Thomas, M.; Chu, A. D.; Hislop, C.; Martin, R. S.; Petri, M. A. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A95 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. THU0124 Variability of Intended Copies for Etanercept in Five Countries. (15th July 2016) Authors: Scheinberg, M.; Castaneda Hernandez, G.; Li, M.; Rao, U.R.; Singh, E.; Mahgoub, E.; Coindreau, J.; O'Brien, J.; Vicik, S.M.; Fitzpatrick, B.; Hassett, B. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 224 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗